For UK Healthcare Professionals Only
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.

For more information about products within the Pathway Portfolio, please click here for prescribing information

Urology

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

  • A full range of strengths available1
  • A first strength to market1
  • Simpler dosing which may help some patients with concordance and compliance1-2
  • The first brand to market1

All of which create a wider offering to patients.

Pathway to Partnership:

Trusted Brands:

  • Bioequivalent to brand originators3
  • Available from mainline wholesalers

Bespoke Support:

  • Price guarantee
  • Individualised rebates on request
Contact a member of our team

Please click here for Neditol® prescribing information

Neditol® XL (tolterodine tartrate) prolonged-release capsules

Indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome4.

  • Bioequivalent to brand originator3

  • Two strengths available: 2mg and 4mg4

  • 2mg recommended dose for patients with severely impaired renal and hepatic function4

CONTACT US TO REQUEST
A COST SAVING REPORT

Neditol® XL is the market leader for prolonged release tolterodine tartrate capsules1.

Neditol® XL is the market leader for prolonged release tolterodine tartrate, as such Neditol® XL is the same price as the UK drug tariff3.

References:

  1. UK Drug Tariff (Accessed June 2026)
  2. Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
  3. REF-00061-1 | Bioequivalence Data on File
  4. Neditol® XL SmPC (Accessed June 2026)

MAT-UK-XLP-0033-1 | June 2026